

Topic Not Assigned A Bill or Rule Number

2021-2022 Legislative Session

Development, drafting or introduction of a proposal relating to
**Biosimilar substitution for interchangeables, as deemed
by the FDA**

Action Intended To Affect: Both Legislative matter and rule
[AbbVie, Inc.](#)

Notified Date: 10/31/2017